Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)

Domínguez-Ortega, J; Almonacid, C; Alvarez-Gutiérrez, FJ; Cisneros, C; Dávila, I; Bañas-Conejero, D; Antelo-Cea, E; de Llano, LP; Flores, HKI; Muñoz-Esquerre, M; Arismendi, E; López-Sainz, G; Bastida, AP; Campos, JGS; Khouadri, K; Zambonino, MA; Otero, DD; Serrano, AC; Fernández-Aracil, C; García-Ródenas, MD; Chiner, E; Boira, I; Auli, BV; García-Rivero, JL; Anaaoui, AH; Abascal-Bolado, B; Campos, RMD; Moguel, IG; Blanco-Aparicio, M; Valverde, TH; Malanda, NM; Cuervo, HG; Apausa, PC; Siverio, PR; Martinez-Moragon, E; Ali-García, I; Castro, JR; Escudero, DL; Silveira, KP; Borit, JC; Tristán, A; Espejo-Castellanos, D; Gall, XM; Fernández, AGB; Sánchez, BM; Lloreda, AL; González, MLP; Kashmiri, DCE

Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)

Background and objective: Although mepolizumab has demonstrated efficacy and effectiveness in the treatment of severe asthma, it is unknown whether the characteristics of patients starting this biologic have changed over the years and whether this impacts their response to mepolizumab. Methods: TYRE...

Descripción completa

Detalles Bibliográficos
Autores:	Domínguez-Ortega, J, Almonacid, C, Alvarez-Gutiérrez, FJ, Cisneros, C, Dávila, I, Bañas-Conejero, D, Antelo-Cea, E, de Llano, LP, Flores, HKI, Muñoz-Esquerre, M, Arismendi, E, López-Sainz, G, Bastida, AP, Campos, JGS, Khouadri, K, Zambonino, MA, Otero, DD, Serrano, AC, Fernández-Aracil, C, García-Ródenas, MD, Chiner, E, Boira, I, Auli, BV, García-Rivero, JL, Anaaoui, AH, Abascal-Bolado, B, Campos, RMD, Moguel, IG, Blanco-Aparicio, M, Valverde, TH, Malanda, NM, Cuervo, HG, Apausa, PC, Siverio, PR, Martinez-Moragon, E, Ali-García, I, Castro, JR, Escudero, DL, Silveira, KP, Borit, JC, Tristán, A, Espejo-Castellanos, D, Gall, XM, Fernández, AGB, Sánchez, BM, Lloreda, AL, González, MLP, Kashmiri, DCE
Tipo de recurso:	artículo
Estado:	Versión publicada
Fecha de publicación:	2026
País:	España
Institución:	Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:	r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:	oai:dnet:r-fisabio___::677c0da8e8b664abf9c8b42939259071
Acceso en línea:	https://fisabio.portalinvestigacion.com/publicaciones/21466
Access Level:	acceso abierto
Palabra clave:	Severe asthma Mepolizumab Clinical remission Biologic therapy Real-world study Spain

id	ES_960c76f8426fda9b2dd2e308e07702c5
oai_identifier_str	oai:dnet:r-fisabio___::677c0da8e8b664abf9c8b42939259071
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)Domínguez-Ortega, JAlmonacid, CAlvarez-Gutiérrez, FJCisneros, CDávila, IBañas-Conejero, DAntelo-Cea, Ede Llano, LPFlores, HKIMuñoz-Esquerre, MArismendi, ELópez-Sainz, GBastida, APCampos, JGSKhouadri, KZambonino, MAOtero, DDSerrano, ACFernández-Aracil, CGarcía-Ródenas, MDChiner, EBoira, IAuli, BVGarcía-Rivero, JLAnaaoui, AHAbascal-Bolado, BCampos, RMDMoguel, IGBlanco-Aparicio, MValverde, THMalanda, NMCuervo, HGApausa, PCSiverio, PRMartinez-Moragon, EAli-García, ICastro, JREscudero, DLSilveira, KPBorit, JCTristán, AEspejo-Castellanos, DGall, XMFernández, AGBSánchez, BMLloreda, ALGonzález, MLPKashmiri, DCESevere asthmaMepolizumabClinical remissionBiologic therapyReal-world studySpainBackground and objective: Although mepolizumab has demonstrated efficacy and effectiveness in the treatment of severe asthma, it is unknown whether the characteristics of patients starting this biologic have changed over the years and whether this impacts their response to mepolizumab. Methods: TYREX was a multicenter, retrospective, observational study conducted in 24 asthma units across Spain to compare baseline clinical and demographic characteristics, and 12-month response to mepolizumab in two cohorts defined by the date of biologic initiation (cohort 1: 2017-2019 vs cohort 2: 2022-2024). Results: Among the 446 patients included in the TYREX study, 191 were classified in cohort 1 and 108 in cohort 2. Cohort 1 had higher baseline exacerbation rates (3.45 vs. 2.40/year; p = 0.0002) and higher blood eosinophils (806 vs. 607 cells/mu L; p = 0.0175). Twelve months after mepolizumab initiation, annual exacerbation rate were reduced to 0.46 in cohort 1 and to 0.51 in cohort 2, ACT scores increased from 14.23 to 21.84 vs. from 15.43 to 21.06; daily oral corticosteroid dependent patients dropped from 33.51% to 9.04% vs. from 12.96% to 2.78%; and clinical remission was achieved in 37.5% vs. 38.5% of patients after 12 months with mepolizumab. In multivariable analysis for 4-domain clinical remission (n = 108), higher baseline ppFEV1 increased the odds of remission while maintenance OCS use decreased them (Figure. 3). In the 3-domain remission model (n = 198), CRSwNP and higher baseline blood eosinophil count increased the odds of remission, whereas maintenance OCS use decreased them (Figure. 3). Conclusion: The decrease over time in severity and blood eosinophilia in asthma patients starting mepolizumab has not shown any impact on the clinical response to the drug.W B SAUNDERS CO LTD2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/21466RESPIRATORY MEDICINEISSN: 09546111ISSNe: 15323064reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:dnet:r-fisabio___::677c0da8e8b664abf9c8b429392590712026-06-11T12:45:17Z
dc.title.none.fl_str_mv	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
title	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
spellingShingle	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024) Domínguez-Ortega, J Severe asthma Mepolizumab Clinical remission Biologic therapy Real-world study Spain
title_short	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
title_full	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
title_fullStr	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
title_full_unstemmed	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
title_sort	Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)
dc.creator.none.fl_str_mv	Domínguez-Ortega, J Almonacid, C Alvarez-Gutiérrez, FJ Cisneros, C Dávila, I Bañas-Conejero, D Antelo-Cea, E de Llano, LP Flores, HKI Muñoz-Esquerre, M Arismendi, E López-Sainz, G Bastida, AP Campos, JGS Khouadri, K Zambonino, MA Otero, DD Serrano, AC Fernández-Aracil, C García-Ródenas, MD Chiner, E Boira, I Auli, BV García-Rivero, JL Anaaoui, AH Abascal-Bolado, B Campos, RMD Moguel, IG Blanco-Aparicio, M Valverde, TH Malanda, NM Cuervo, HG Apausa, PC Siverio, PR Martinez-Moragon, E Ali-García, I Castro, JR Escudero, DL Silveira, KP Borit, JC Tristán, A Espejo-Castellanos, D Gall, XM Fernández, AGB Sánchez, BM Lloreda, AL González, MLP Kashmiri, DCE
author	Domínguez-Ortega, J
author_facet	Domínguez-Ortega, J Almonacid, C Alvarez-Gutiérrez, FJ Cisneros, C Dávila, I Bañas-Conejero, D Antelo-Cea, E de Llano, LP Flores, HKI Muñoz-Esquerre, M Arismendi, E López-Sainz, G Bastida, AP Campos, JGS Khouadri, K Zambonino, MA Otero, DD Serrano, AC Fernández-Aracil, C García-Ródenas, MD Chiner, E Boira, I Auli, BV García-Rivero, JL Anaaoui, AH Abascal-Bolado, B Campos, RMD Moguel, IG Blanco-Aparicio, M Valverde, TH Malanda, NM Cuervo, HG Apausa, PC Siverio, PR Martinez-Moragon, E Ali-García, I Castro, JR Escudero, DL Silveira, KP Borit, JC Tristán, A Espejo-Castellanos, D Gall, XM Fernández, AGB Sánchez, BM Lloreda, AL González, MLP Kashmiri, DCE
author_role	author
author2	Almonacid, C Alvarez-Gutiérrez, FJ Cisneros, C Dávila, I Bañas-Conejero, D Antelo-Cea, E de Llano, LP Flores, HKI Muñoz-Esquerre, M Arismendi, E López-Sainz, G Bastida, AP Campos, JGS Khouadri, K Zambonino, MA Otero, DD Serrano, AC Fernández-Aracil, C García-Ródenas, MD Chiner, E Boira, I Auli, BV García-Rivero, JL Anaaoui, AH Abascal-Bolado, B Campos, RMD Moguel, IG Blanco-Aparicio, M Valverde, TH Malanda, NM Cuervo, HG Apausa, PC Siverio, PR Martinez-Moragon, E Ali-García, I Castro, JR Escudero, DL Silveira, KP Borit, JC Tristán, A Espejo-Castellanos, D Gall, XM Fernández, AGB Sánchez, BM Lloreda, AL González, MLP Kashmiri, DCE
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	Severe asthma Mepolizumab Clinical remission Biologic therapy Real-world study Spain
topic	Severe asthma Mepolizumab Clinical remission Biologic therapy Real-world study Spain
description	Background and objective: Although mepolizumab has demonstrated efficacy and effectiveness in the treatment of severe asthma, it is unknown whether the characteristics of patients starting this biologic have changed over the years and whether this impacts their response to mepolizumab. Methods: TYREX was a multicenter, retrospective, observational study conducted in 24 asthma units across Spain to compare baseline clinical and demographic characteristics, and 12-month response to mepolizumab in two cohorts defined by the date of biologic initiation (cohort 1: 2017-2019 vs cohort 2: 2022-2024). Results: Among the 446 patients included in the TYREX study, 191 were classified in cohort 1 and 108 in cohort 2. Cohort 1 had higher baseline exacerbation rates (3.45 vs. 2.40/year; p = 0.0002) and higher blood eosinophils (806 vs. 607 cells/mu L; p = 0.0175). Twelve months after mepolizumab initiation, annual exacerbation rate were reduced to 0.46 in cohort 1 and to 0.51 in cohort 2, ACT scores increased from 14.23 to 21.84 vs. from 15.43 to 21.06; daily oral corticosteroid dependent patients dropped from 33.51% to 9.04% vs. from 12.96% to 2.78%; and clinical remission was achieved in 37.5% vs. 38.5% of patients after 12 months with mepolizumab. In multivariable analysis for 4-domain clinical remission (n = 108), higher baseline ppFEV1 increased the odds of remission while maintenance OCS use decreased them (Figure. 3). In the 3-domain remission model (n = 198), CRSwNP and higher baseline blood eosinophil count increased the odds of remission, whereas maintenance OCS use decreased them (Figure. 3). Conclusion: The decrease over time in severity and blood eosinophilia in asthma patients starting mepolizumab has not shown any impact on the clinical response to the drug.
publishDate	2026
dc.date.none.fl_str_mv	2026
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	https://fisabio.portalinvestigacion.com/publicaciones/21466
url	https://fisabio.portalinvestigacion.com/publicaciones/21466
dc.language.none.fl_str_mv	Inglés
language_invalid_str_mv	Inglés
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	W B SAUNDERS CO LTD
publisher.none.fl_str_mv	W B SAUNDERS CO LTD
dc.source.none.fl_str_mv	RESPIRATORY MEDICINE ISSN: 09546111 ISSNe: 15323064 reponame:r-FISABIO. Repositorio Institucional de Producción Científica instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str	Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str	r-FISABIO. Repositorio Institucional de Producción Científica
collection	r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869413903436349440
score	15.812429

Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024)

Similares en LA Referencia